You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Vaccines

I'm Derek O'Hagan. I work for GSK Vaccines. I research in Cambridge. I'm going to be talking about vaccine adjuvants. Although I'm an employee of GSK Vaccines, the presentation I'm going to make really reflects my experience across a number of companies, and it doesn't really express the policy of GSK.
So in trying to define vaccine adjuvants and what they are, it's not an easy task to accomplish. Essentially, they are defined by what they do. They enhance the immune response to a vaccine antigen. So since there's no clear definition, there are many, many diverse substances in the literature that have been described as vaccine adjuvants, particularly in a pre-clinical setting. If we try to understand a little better those that have progressed to clinical trials, we can get a better appreciation of some of the materials, because a smaller percentage of advanced trials. And even a very small percentage of these have eventually been included in licensed vaccines. And these are the adjuvants I'm mostly going to focus on for obvious reasons. It's a very diverse area. There many materials, but I'm going to focus on those that have been most advanced.